Global Blood Therapeutics Inc (NASDAQ:GBT) reported recent business progress and financials for the 3rd quarter ended 30 September 2020. The highlights are-
- During the period, total net product sales were US$36.9 million, resulting from sales of Oxbryta.
- In the September quarter, the Company recorded over 1k new prescriptions of Oxbryta, despite the upsurge in COVID-19 cases in the US.
- GBT disclosed that new prescriptions were higher during August and September, with some weeks reaching pre-pandemic levels.